STAC3 Disorder

From WikiMD's Food, Medicine & Wellness Encyclopedia

Alternate names[edit | edit source]

Congenital myopathy cleft palate and malignant hyperthermia; Congenital myopathy - cleft palate - malignant hyperthermia; Congenital myopathy-cleft palate-malignant hyperthermia syndrome; Congenital myopathy with myopathic facies, scoliosis, and malignant hyperthermia; Bailey-Bloch congenital myopathy; Native American myopathy

Definiton[edit | edit source]

STAC3 Disorder is a genetic condition that affects the muscles and skeleton. The main features are muscle weakness present at birth, club foot, fixed joints (joint contractures), and curvature of the spine.

Epidemiology[edit | edit source]

STAC3 disorder was first found in individuals from the Lumbee Native American Tribe in North Carolina. The condition affects an estimated 1 in 5,000 people in this population. STAC3 disorder has since been found in other populations worldwide, though its prevalence is not known.

Cause[edit | edit source]

  • STAC3 disorder is caused by mutations in the STAC3 gene.
  • This gene provides instructions for making a protein that plays a role in the tensing (contraction) of skeletal muscles.
  • Muscle contractions are triggered by changes in the concentration of certain charged atoms (ions) in muscle cells.
  • The STAC3 protein aids in the process that triggers the release of calcium ions within muscle cells to start (initiate) muscle contraction.
  • The STAC3 protein interacts with two structures in muscle cells that are critical for calcium ion flow, dihydropyridine receptor (DHPR) and ryanodine receptor 1 (RYR1).
  • However, STAC3's role in this formation is unclear.
  • RYR1 forms a channel (the RYR1 channel) through which calcium ions can flow.
  • In response to certain signals, DHPR turns on (activates) the RYR1 channel, and the activated RYR1 channel releases calcium ions stored in structures inside muscle cells.
  • The resulting increase in the calcium ion concentration within muscle cells stimulates muscles to contract, allowing the body to move.

Gene mutation[edit | edit source]

  • STAC3 gene mutations reduce the amount or impair the function of the STAC3 protein.
  • Although the mechanism is unclear, studies show that a shortage of functioning STAC3 protein prevents the release of stored calcium ions by RYR1 channels.
  • A disruption in calcium ion release prevents muscles from contracting normally, leading to the muscle weakness characteristic of STAC3 disorder.
  • It is unclear how these STAC3 gene mutations lead to malignant hyperthermia in susceptible individuals.
  • Mutations in other genes related to malignant hyperthermia activate the RYR1 channel improperly in response to certain drugs.
  • As a result, large amounts of calcium ions are released from storage within muscle cells, causing skeletal muscles to contract abnormally.
  • An increase in calcium ion concentration also activates processes that generate heat (leading to hyperthermia) and produce excess acid (leading to acidosis). It is unknown if STAC3 gene mutations have a similar effect on RYR1 channel activity.

Inheritance[edit | edit source]

Autosomal recessive inheritance, a 25% chance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Signs and symptoms[edit | edit source]

The following list includes the most common signs and symptoms in people with STAC3 disorder. These features may be different from person to person. Some people may have more symptoms than others and symptoms can range from mild to severe. This list does not include every symptom or feature that has been described in this condition.

STAC3 disorder is very rare and how the symptoms change over time has not been well described.

  • The muscle weakness and curvature of the spine tend to slowly get worse, although some people with STAC3 disorder have mild symptoms that don't change.
  • Most adults with STAC3 disorder are shorter than average and may have delayed motor skills (like walking and running).
  • Intelligence is usually normal.
  • A few have severe symptoms that result in very serious respiratory and feeding difficulties.

Diagnosis[edit | edit source]

STAC3 disorder (also known as Native American myopathy) should be suspected in individuals with the following clinical and laboratory findings.[1][1].

Clinical findings

  • Congenital myopathy
  • Congenital weakness
  • Myopathic facies, characterized by ptosis, inability to raise corners of mouth, and (in some individuals) hollowed-out cheeks from loss of facial musculature, which may cause an open-mouthed expressionless appearance with downturned corners of the mouth. Over time, the face often becomes long and narrow.

Musculoskeletal anomalies

Characteristic facial features.

  • Myopathic facies, micrognathia, and palatal anomalies can be seen in a number of neuromuscular disorders of varying etiologies; the characteristics that best distinguish STAC3 disorder from other conditions include low-set and/or posteriorly rotated ears, short and/or downslanting palpebral fissures, and telecanthus.
  • Short stature
  • Susceptibility to malignant hyperthermia

Laboratory findings. Creatine kinase baseline levels are most often normal .

Establishing the Diagnosis The diagnosis of STAC3 disorder is established in a proband with clinical findings consistent with Suggestive Findings and biallelic pathogenic variants in STAC3 identified by molecular genetic testing.

Treatment[edit | edit source]

At present, no treatment halts or reverses the manifestations of STAC3 disorder. Treatment of musculoskeletal involvement is symptomatic and ideally provided by a multidisciplinary neuromuscular team to address the following:[2][2].

  • Occupational and physical therapy needs regarding range of motion and mobility
  • Use of adaptive devices for mobility and activities of daily living
  • Feeding difficulties
  • Speech delays
  • Scoliosis
  • Respiratory insufficiency
  • Due to the medical comorbidities in STAC3 disorder, decisions regarding type and timing of cleft palate surgery should be determined by a multidisciplinary craniofacial team.
  • Depending on the structure of the managing craniofacial team, interventions for ptosis may be undertaken by an ophthalmologist as part of team care, or as an insertion intervention.


References[edit | edit source]

  1. Webb BD, Manoli I, Jabs EW. STAC3 Disorder. 2019 Jun 20. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542808/
  2. Webb BD, Manoli I, Jabs EW. STAC3 Disorder. 2019 Jun 20. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542808/


NIH genetic and rare disease info[edit source]

STAC3 Disorder is a rare disease.


This article is a stub.

Help WikiMD grow by registering to expand it.
Editing is available only to registered and verified users.
About WikiMD: A comprehensive, free health & wellness encyclopedia.

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Deepika vegiraju